The ability to engender potent neoantigen- or tumor-associated antigen–specific CD8+ cytotoxic T cell immunity is indispensable to the long-term therapeutic efficacy of essentially all cancer treatment strategies. This evidence concerns the gene CD8A and neoplasm.